

Iztok Hozo –Curriculum Vitae

Academic Record and Experience:

1994 - present **Indiana University Northwest** Gary, IN
Professor of Mathematics

- Came to Indiana University NW in 1994.
Promoted to Associate Professor with tenure in 1998.
Promoted to Professor in 2003.
- Recipient of 2014 Executive Vice Chancellor of Academic Affairs Distinguished Research/Creative Activity Award
- Recipient of 2003 President's Award for Teaching Excellence (Indiana University system-wide award – 5000 full-time faculty).
- Recipient of University Research Award 2006
- Recipient of College of Arts and Sciences Research Award in 2006.
- Recipient of 2001 and 2003 Teaching Excellence Recognition Award for Indiana University Northwest
- Selected into the 2000 Faculty Colloquium on Excellence in Teaching (FACET), a highly selective group of outstanding teachers throughout Indiana University.
- 1998 and 1999 Teaching Excellence Recognition Award for Indiana University Northwest.
- Recipient of the 1997 IUN Founders' Day Teaching Excellence Award (Outstanding Teaching Award).
- Member of the Indiana University Graduate Faculty with full status. This represents endorsement of my research record and encouragement to teach graduate level courses.
- The Editorial Board of the 2013 IMIA Yearbook of Medical Informatics has selected my article entitled: "[Dual processing model of medical decision-making](#)", BMC Med Inform Decis Mak 2012;12(94):239-47 for listing in the Yearbook as one of the best articles from the literature in medical informatics published in the past year.
The Yearbook has appeared in August 2013 and is made available to over 20,000 members of the healthcare and biomedical scientific communities through both a print version and online access. It reaches members in more than 40 societies participating to IMIA worldwide.
- Current Research: Writing a series of papers in the area of medical decision-making in collaboration with various medical research groups. The following topics are of current interest:
 1. Game Theory Applications to Medical practice: Applying several concepts of simple game theory to explain some aspects of clinical practice. This is a very fresh and interesting line of investigation that received plenty of immediate attention. We recently published a paper: "[Modern health care as a game theory problem](#)" which has been a centerpiece of a piece in Washington Post <http://www.washingtonpost.com/news/wonkblog/wp/2015/09/16/how-the-doctor-patient-relationship-has-become-a-prisoners-dilemma/>.
 2. Methods of estimating statistical measures of dispersion from limited data reported in order to perform meta-analysis of clinical trials. Our paper "[Estimating the mean and variance from the median, range, and the size of a sample](#)" has recently crossed the threshold of 2000 citations in twelve years (since 2005). Check [Google Scholar](#) for the most recent number!
 3. Mathematical modeling in medical decision making; designing easy to use tools for medical doctors that enable them to analyze the influence of various parameters on their decisions in various models. Using Excel (with extensive use of VBA macros), Stata (calling procedures in R or Winbugs when necessary) or various other software packages to create easy to use

modules that help understand the processes we are researching.

4. Developing methods for assessing medical innovations; Meta-Analysis of clinical trials; Calculation of life expectancy from AUC (area-under-curve) of published survival curves. Extraction of summary therapeutic parameters from multiple reports on clinical trials. We published the most comprehensive analysis about treatment success in clinical medicine (cancer) showing that discoveries of new treatments are linked to the ethical principle of “equipose”/“uncertainty principle” (which at the same time defines limits of discoverability in clinical research and drives therapeutic advances in clinical medicine). The work has been described as “the law of clinical discoveries” and has received attention of the press all over the world with requests for many interviews for our project leader, Dr. Djulbegovic. The paper “When should potentially false research findings be considered acceptable?” selected as the Press Release by the PLoS Medicine & featured in Scientific American.
 5. Benefit/risk hypothesis testing model and gamma statistical error. Developing statistical hypothesis testing to account for uncertainties in the benefit/risk decision model, we have developed over the last several years.
 6. Acceptable Regret Theory, developing a Decision theory – based model for incorporating acceptable regret in medical decision making. The paper “Acceptable regret: an extension of basic decision-making concept to medical and clinical research arena” was selected for special presentation at the Society for Judgment and Decision Making in the NSF supported Symposium on “Application and Innovation: Lessons from Medical Decision-Making”, November 14-17, Chicago, 2008
 7. Comparison of simple EBM-DA model (“our” model) with more complex model (e.g. Markov model) in deciding on the threshold for decision making.
 8. Calculation of optimal timing of BMT (bone-marrow transplant).
- Participated as a **consultant/research specialist** in the following grant projects (below). I usually help develop mathematical model for the project, provide theoretical foundation and write software routines (using Access, Maple, Mathematica, Excel, Stata, or another database/ statistical/ mathematical software package) to run simulations and calculations for the project. In most of these projects the lead Principal Investigator was Dr. B. Djulbegovic, my collaborator from University of South Florida. A couple of grants are with Dr. Dipika Gupta, from Indiana University School of Medicine – Northwest.
 1. **Co – Principal Investigator:** 2013-2014: “**Peptidoglycan recognition proteins – a role in asthma**”, \$ 4,000. Indiana University Research Support Grant. With Dr. Gupta (Indiana University School of Medicine); **Purpose:** Provide funds for lab samples and equipment in order to continue our successful (published) research.
 2. **Consultant:** 2009 – 2014: “**Development of Evidence-Based Clinical Decision Support System to Aid Prognostication in Terminally Ill Patients**”, \$4,295,000. USAMRMC NO: W81XWH-09-2-0175. **Purpose:** to develop computer decision-support system for better prognostication in life expectancy and improvement in decision making in terminally ill patients.
 3. **Co – Principal Investigator:** 2013-2014: “**Genetic link of peptidoglycan proteins with inflammatory bowel disease**”, \$ 67,000. Indiana University Collaborative Research Grant. With Dr. Gupta (Indiana University School of Medicine); **Purpose:** Provide funds for research assistant and lab equipment in order to continue our successful (published) research.
 4. **Consultant:** 2008 – 2013: “**Myeloma Health Outcome Database**”, 99,000/yr. Millennium Pharmaceuticals, **Purpose:** To update and create a new web-based searchable health outcome database of randomized trials in multiple myeloma.
 5. **Consultant:** 2010 – 2013: “**When are clinical trials ethical for both future patients and study patients**”, \$ 595,410. Bankhead-Coley Cancer Res Program (Florida) **Purpose:** to identify those situations where the line between research and practice is less blurred, which in turn will help with design, enrollment and funding decisions of clinical trials.

6. Consultant: 2009 – 2011: “**Treatment Success and the Ethical Principle of Equipoise**”, \$631,183. NIH/NCI, 1R01CA140408-01. Purpose: the purpose of this grant is to assess if the efficiency and patterns of clinical therapeutic discoveries reflect the ethical principle of equipoise.
 7. Consultant: 2007 – 2010: “**Quality of Research on Treatment Harms in Cancer**”, \$175,000/yr. NIH/NCI 1R01 NRO10328-01. Purpose: The purpose of this proposal is to perform in-depth critical appraisal treatment-related toxicities in randomized trials sponsored by the NIH/NCI.
 8. Consultant: 2005 – 2007: “**Evaluation of the quality of clinical trials**”, \$175,000, 1 R01 NS052956-01, NIH/ORI. Purpose: to assess the quality of design, conduct and analysis of cancer randomized trials.
 9. Consultant: 2002 – 2005: “**Equipoise and the research integrity of clinical trials**”, \$200,000, 1 R01 NS044417-01, NIH/ORI. Purpose: This proposal focuses on the understanding of equipoise, which is the fundamental principle on which nearly the entire system of human experimentation stands and its relation to the results of clinical trials.
 10. Consultant: 2002 – 2005: “**Blood vs. bone marrow stem transplant**”, \$ 200,000, 1R01HL71650-01; NIH/NHLBI. Purpose: to perform individual-patient data meta-analysis to assess the role of allogeneic peripheral blood stem cell transplant vs. bone-marrow in patients with hematological malignancies.
 11. Consultant: 2001 – 2002: “**Myeloma health outcome database of randomized controlled trials**”, \$67,000. Millennium (agreement No: 201098). Purpose: To create a searchable health outcome database of randomized trials in multiple myeloma
- Mini-Course: Invited to organize a mini-course describing my research methods by the European School of Oncology with a group of international researchers held in July of 2004 in Antwerp, Belgium.
 - Co-wrote the Solution Manuals for the 8th edition of the “Finite Mathematics” and 7th edition of the “Mathematics” by Mizrahi-Sullivan published by Wiley and Sons. Participated in extensive revisions of several subsequent editions of both books (mid 2000’s).
 - Curriculum Development: Developed two new Bachelor of Science in Mathematics programs at Indiana University Northwest.
 - Developing new courses, for example *Mathematics and Politics* (supported by the IU-NSF grant “Mathematics Throughout the Curriculum” – presented a talk at the Joint AMS-MAA conference in New Orleans) and *Mathematics in the Workplace* course designed for the Swingshift College (students working in shifts in local steel mills and attending our university).
 - Co-designer of a project transforming our developmental mathematics classes into technology-based, modular courses (which was unsuccessful due to logistical difficulties).
 - Director of a pre-calculus/calculus reform project “*Calculators for Commuters*” at the Indiana University Northwest incorporating technology into curriculum. The project was funded by the Strategic Directions Initiative of Indiana University (\$20,000), and enabled us to set up a bank of about 100 calculators (TI-83 graphing calculators) for our students to lease on semester-by-semester basis.
 - Led Gary Youth Gifted and Talented Program for talented 6th, 7th and 8th grade students from Gary Public School Corporation on and off for several years. The four-week long workshop included untraditional topics from mathematics curriculum such as topology (Shape of Space), graph theory (Four color theorem), logic and problems solving techniques.
 - Teaching various junior- and senior-level courses (probability, statistics, numerical methods, and operations research, abstract algebra, real analysis, measure theory and topology), as well as several freshman and sophomore courses (intermediate and college algebra, pre-calculus, finite mathematics, calculus I, calculus II, and calculus III).
 - Member of various Committees on Campus, within the department, division, and university-wide. I often serve on some of the following committees:
Executive Committee - committee elected by Faculty Organization;
Faculty Board of Review – elected committee;
Salary Committee – elected committee;
Campus Promotion and Tenure Committee – elected committee;
Arts and Science Promotion and Tenure Committee – elected committee;

IUN Council – campus wide committee consisting of all constituencies deciding on strategic directions and advising senior administration on day-to-day operations of the campus (meets monthly).

Grants and Research Committee – awards time-releases, fellowships, and grant-in-aid proposals;

Arts and Science Curriculum Committee – work-intensive committee dealing with curriculum issues and new programs.

Budgetary Affairs Committee – a committee dealing with the always-diminishing budget of the university.

Some of the other committees I served on in the past several years at IUN: Computer Committee, Teaching Committee, Faculty Affairs Committee, Academic Affairs, Scholarship Committee ...

- P-16 committee – appointed to a committee with membership that includes faculty, administrators from IU, as well as superintendents from public school systems in Indiana, which is trying to improve the integration of educational experience for students from Preschool to Higher Education.
- Summer Faculty Research Fellowships at IUN, summers of 1995, 1997, 2002, 2004, 2006.

1988 – 1994 University of Michigan Ann Arbor, MI

Lecturer, Research Assistant and Teaching Assistant

- Ph. D. in Mathematics (1993).
- Participated in the Calculus Reform program at the University of Michigan in 1993-1994.
- Rackham Predoctoral Fellowship (1992-1993).
- N.S.F. support (summers 1990-1992). Research Assistant (1991 and 1992).

1983 – 1988 University of Sarajevo Sarajevo, Bosnia

- B. S. in Mathematics (1988).
- Research in Measure Theory and Real Analysis.
- Hasan Brkic Golden Medal of University of Sarajevo for Outstanding Performance;

1987 – 1988 IRIS Research Institute Sarajevo, Bosnia

- Developed software in programming languages DBase IV and C for IRIS, (summers 1987 and 1988).

- I usually belong to at least one of the professional organizations in the field: **Mathematical Association of America** or **American Mathematical Society**, and/or in the profession: **American Association of University Professors**.

**Professional
Societies**

- 1) **Hozo I** and H.I. Miller, "On Riemann's Theorem About Conditionally Convergent Series", *Matematički Vesnik*, (1986), **38**: 279-283.
- 2) **Hozo I**, "The eigenvalues of the Laplacian of the homology of the Lie algebra corresponding to a poset", [Electronic Journal of Combinatorics](#), Vol. 2 (1995) #R14 (42 pages).
- 3) B.Djulgovic, **Hozo I**, I. Abdomerovic, S. Pudar-Hozo, "Diagnostic Entropy as a function of therapeutic benefit/risk ratio", *Medical Hypothesis* (1995) **45**: 503-509.
- 4) **Hozo I**, "Inclusion of the poset homology into the Lie algebra homology", [Journal of Pure and Applied Algebra](#), (1996) **111**: 169-180.
- 5) **Hozo I**, B. Djulgovic, "Calculating confidence intervals for threshold and posttest probabilities", [M.D. Computing](#). (1998); **15**:110-115
- 6) Djulgovic B, **Hozo I**, Fields K, Sullivan D. "High Dose Chemotherapy in the Adjuvant Treatment of Breast Cancer: Benefit/Risk Analysis." [Cancer Control](#) (1998); **5**:26-37
- 7) Djulgovic B and **Hozo I**. "Acting on evidence can only be done within the context of decision analysis." *BMJ* (1998); July 29 (<http://www.bmj.com/cgi/eletters/317/7151/139>)
- 8) **Hozo I**, B. Djulgovic, "Computer program for the Diagnosis and Treatment of Polycythemia Rubra Vera", [M.D. Computing](#). (1999); **16**:83-89
- 9) Djulgovic B, **Hozo I**, McMasters K, Schwartz A. "Regret in Medical Decision Making " *Med Hypotheses* (1999); **53**:253-259.
- 10) **Hozo I**, Djulgovic B. "Using Internet to Calculate Clinical Action Thresholds " *Comp Biomed Res* (1999); **32**:168-185.
- 11) Djulgovic B, **Hozo I**, Lyman GH. "Talking about treatment". *Ann Intern Med* (2000); **132**: 93-94.
- 12) Djulgovic B, **Hozo I** and Lyman G. "Linking Evidence-based Medicine Therapeutic Summary Measures to Clinical Decision Analysis". *MedGenMed*, January 13, (2000) (≈20 pages)
- 13) Djulgovic B, Adams J, Lyman G, Lacevic M, **Hozo I**, Greenwich M, and Bennett C. "Evaluation and Appraisal of Randomized Controlled Trials in Myeloma" *Annals Oncol* (2001); **12**: 1-7
- 14) Djulgovic B, **Hozo I**. "At what degree of belief in research hypothesis a trial in humans is justified?", *Journal of Evaluation in Clinical Practice* (2002); **8**(2), 269-276.
- 15) Soares HP, Kumar A, Daniels S, Swann S, Cantor A, **Hozo I**, Clark M, Serdarevic F, Gwede C, Trotti A, Djulgovic B "Evaluation of New Treatments in Radiation Oncology: Are They Better Than Standard Treatments?" *JAMA (Journal of the American Medical Association)* 293.8 (2005) 970-78. The same issue of JAMA also contained an editorial addressing our article titled "The Case for Randomized Trials in Cancer Treatment. New Is Not Always Better" by A. Grann and V. Grann.
- 16) Pudar Hozo S, Djulgovic B, **Hozo I**, "Estimating the mean and variance from the median, range, and the size of a sample." *BMC Medical Research Methodology* 5:13 (2005)
- 17) **Stem Cell Trialists Group**¹. "Allogeneic Peripheral Blood Stem Cell Transplant vs. Bone Marrow Transplant in the Management of Hematological Malignancy" An Individual Patient Data Meta-Analysis of 9 Randomized Trials. *Journal of Clinical Oncology*. 23.22 (2005): 5074-87;
- 18) **Hozo I**, Djulgovic B, Clark O and Lyman G, "Use of re-randomized data in meta-analysis" *BMC Medical Research Methodology* 5:17 (2005)

¹ I am a member of this group.

- 19) Kumar A, Soares PH, Wells R, Clarke M, **Hozo I**, Bleyer A, Reaman G, Chalmers I, and Djulbegovic B, "*Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group*", British Medical Journal (2005); 331; 1295 BMJ, doi:10.1136/bmj.38628.561123.7C (published 18 November 2005).
The same issue of British Medical Journal also contained an editorial addressing our article titled: "*In praise of uncertainty*" by F. Godlee.
- 20) **Stem Cell Trialists Group**¹. "*Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs. bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration.*" Bone Marrow Transplant (2006); 38:539-546.
- 21) Djulbegovic B, **Hozo I**. "*When should potentially false research findings be considered acceptable?*", PLoS Med. (2007) Feb;4(2):e26.
- 22) Djulbegovic B, **Hozo I**, Lyman GH, "*Estimating net benefits and harms of screening mammography in women age 40-49*", Annals Of Internal Medicine [Ann Intern Med], ISSN: 1539-3704, (2007) Dec 18; Vol. 147 (12), pp. 882.
- 23) Djulbegovic B, Kumar A, Soares HP, **Hozo I**, Bepler G, Clarke M, Bennett CL, "*Treatment Success in Cancer. [New Cancer Treatment Successes Identified in Phase III randomized controlled trials conducted by the National Cancer Institute -sponsored Cooperative Oncology Groups: 1955-2000]*", Archives Of Internal Medicine [Arch Intern Med], ISSN: 0003-9926, (2008) Mar 24; Vol. 168 (6), pp. 632-42.
- 24) Djulbegovic B, Kumar A, Bepler G, Clarke M, Soares HP, **Hozo I**, Bennett CL. "*Treatment success in cancer-reply*". Arch Intern Med (2008);168:2173-2174
- 25) **Hozo I**, Djulbegovic B, "*When is diagnostic testing inappropriate or irrational? Acceptable regret approach*", Med Decis Making (2008);28:540-553.
- 26) **Hozo I**, Schell MJ, Djulbegovic B. "*Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach.*" Semin Hematol (2008);45:50-159
- 27) **Hozo I**, Djulbegovic B, "*Will insistence on practicing medicine according to expected utility theory lead to an increase in diagnostic testing? Reply to Dekay's commentary : Physicians' anticipated regret and diagnostic testing.*", Med Decis Making (2009);29:320-324.
- 28) Kumar A, List A, **Hozo I**, Komrokji R, Djulbegovic B, "*Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis*", Haematologica (2009); 94: doi: 10.3324/haematol.2009.017764
- 29) Herold CI, Djulbegovic B, **Hozo I**, Lyman GH, "*Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer.*" Breast Cancer Res Treat. (2010) Volume 121, Number 3, 771-776, DOI: 10.1007/s10549-009-0564-1
- 30) Tsalatsanis A, **Hozo I**, Vickers A and Djulbegovic B, "*A regret theory approach to decision curve analysis: A novel method for eliciting decision makers' preferences and decision-making*", BMC Medical Informatics and Decision Making (2010), 10:51doi:10.1186/1472-6947-10-51
- 31) Djulbegovic B, **Hozo I**, at all. "*Optimism bias leads to inconclusive results - an empirical study*", J Clin Epidemiol (2011) Jun, 64:583-93
- 32) Miladinovic B, Kumar A, **Hozo I** and Djulbegovic B, "*Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance*" BMC Medical Research Methodology (2011), 11:55.

- 33) Tsalatsanis A, Barnes L, **Hozo I**, Skvoretz J, Djulbegovic B, “*A social network analysis of treatment discoveries in cancer*”, PLoS ONE (2011) 6(3): e18060., doi:10.1371/journal.pone.0018060.
- 34) Kumar A, **Hozo I**, Wheatley K, Djulbegovic B, “*Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.*”, Am J Hematol (2011) Jan, 86:18-24
- 35) Djulbegovic B, **Hozo I**, Greenland S, "Uncertainty in Clinical Medicine", Encyclopedia of Medical Philosophy;2, edited by Gifford F, Elsevier (2011). In: Dov M. Gabbay and John Woods, editors, Handbook of The Philosophy of Science: Philosophy of Medicine. San Diego: North Holland, (2011), pp. 299-356.
- 36) Athanasios Tsalatsanis, Laura E Barnes, **Iztok Hozo** and Benjamin Djulbegovic, "Extensions to Regret-based Decision Curve Analysis: An application to hospice referral for terminal patients", BMC Medical Informatics and Decision Making (2011), 11:77
- 37) Djulbegovic B, **Hozo I**. “*When is it rational to participate in a clinical trial? a game theory approach incorporating trust, regret and guilt*”, BMC Medical Research Methodology (2012), 12:85
- 38) Djulbegovic B, **Hozo I**, Beckstead J Tsalatsanis A, Pauker GS. “*Dual processing model of medical decision-making*”, BMC Medical Informatics and Decision Making. (2012), 12:94
- 39) Miladinovic B, **Hozo I**, B Djulbegovic. “*Trial sequential boundaries for cumulative meta-analysis.*” The Stata Journal, 2013; 13(1), pp 1-15.
- 40) Miladinovic B, Kumar A, Mhaskar R, Georgiev H, **Hozo I**, Djulbegovic B. “*Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results due to the risk of random error*”, J Clin Epidemiol. (2013) Jun;66(6):654-9.
- 41) Miladinovic B, Kumar A, **Hozo I**, Djulbegovic B. “*Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: A case study of meta-analyses of multiple myeloma trials.*” Contemporary Clinical Trials 34 (2013) 257–261
- 42) Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, **Hozo I**, Tu D, Stanton HA, Booth CM, Meyer RM. “*Treatment Success in Cancer: Industry versus Publicly Sponsored Randomized Controlled Trials - A Systematic Review*”, PLoS One. (2013);8(3):e58711. doi: 10.1371/journal.pone.0058711. Epub 2013 Mar 21.
- 43) Zulfiqar F, **Hozo I**, Rangarajan S, Mariuzza R.A., Dziarski R, Gupta D. “*Genetic association of peptidoglycan recognition protein variants with inflammatory bowel disease*”, PLoS One. (2013) Jun 19;8(6):e67393.
- 44) John P.A. Ioannidis, **Iztok Hozo**, Benjamin Djulbegovic, "Optimizing type I and II error pairs for research inferences", J Clin Epidemiol. (2013) Aug;66(8):903-910.
- 45) Ioannidis J, **Hozo I**, Djulbegovic B, “*Improving the drug development process: more not less randomized trials*”, JAMA. 2014; 311(4):355-356. doi:10.1001/jama.2013.283742.
- 46) Miladinovic B, Chaimani A, **Hozo I**, B Djulbegovic. “*Indirect treatment comparison.*” The Stata Journal, 2014; 14(1), pp 76-86.
- 47) Djulbegovic B, Elqayam S, Reljic T, **Hozo I**, Miladinovic B, Tsalatsanis A, Kumar A, Beckstead J, Taylor Se, Cannon-Bowers J. “*How do physicians decide to treat: an empirical evaluation of the threshold model*”, BMC Medical Informatics and Decision Making.2014, 14:47 DOI: 10.1186/1472-6947-14-47

² This is a book chapter!

- 48) John P.A. Ioannidis, **Iztok Hozo**, Benjamin Djulbegovic, “*Study Design and the Drug Development Process—Reply*”, JAMA. 2014;311(19):2023-2024. doi:10.1001/jama.2014.3829
- 49) R Dziarski; DR Kashyap; A Rompca; A Gaballa; JD Helmann; J Chan; CJ Chang; **I Hozo**; D Gupta, “*Peptidoglycan Recognition Proteins Kill Bacteria by Inducing Oxidative, Thiol, and Metal Stress*”, PLoS Pathog 10(7): e1004280. doi:10.1371/journal.ppat.1004280 (2014)
- 50) H Wao, R Mhaskar, A Kumar, B Miladinovic, T Guterbock, **I Hozo**, B Djulbegovic, “*Uncertainty about effects is a key factor influencing institutional review boards’ approval of clinical studies*”, Annals of Epidemiology 24 (2014) 734 – 740 doi: 10.1016/j.annepidem.2014.06.100. Epub 2014 Jul 10. .
- 51) A Cucchetti, B Djulbegovic, A Tsalatsanis, A Vitale, **I Hozo**, M Cescon, F Piscaglia, G Ercolani, F Tuci, U Cillo, AD Pinna “*When to perform hepatic resection for intermediate stage hepatocellular carcinoma: a regret-based approach*” Hepatology. 2014 Jul 21. doi: 10.1002/hep.27321. (2014)
- 52) Benjamin Djulbegovic, **Iztok Hozo** “*Effect of Initial Conditions on Reproducibility of Scientific Research*” Acta Informatica Medica, Year 2014, Volume 22, Issue 3, Pages 156-159
- 53) Benjamin Djulbegovic, **Iztok Hozo**, John P.A. Ioannidis, “*Modern health care as a game theory problem*“, European Journal of Clinical Investigation, Volume 45, Issue 1, pages 1–12, January 2015 (2015)
- 54) Benjamin Djulbegovic, Jef van den Ende, Robert M. Hamm, Thomas Mayrhofer, **Iztok Hozo** and Stephen G. Pauker “*When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation*” Eur J Clin Invest. 2015 May;45(5):485-93. doi: 10.1111/eci.12421. Epub 2015 Mar 9.
- 55) Djulbegovic B, Tsalatsanis A, **Hozo I** “*Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease*” J Eval Clin Pract. 2015 Nov 11. doi: 10.1111/jep.12473. [Epub ahead of print]
- 56) Tsalatsanis A, **Hozo I**, Kumar A, Djulbegovic B “*Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing.*” PLoS ONE 10(8): e0134800. doi:10.1371/journal.pone.0134800 (2015)
- 57) Benjamin Djulbegovic, Jef van den Ende, Robert M. Hamm, Thomas Mayrhofer, **Iztok Hozo** “*Rationality, Practice Variation, and Person-Centered Health Policy: a Threshold Hypothesis*” J Eval Clin Pract. 2015 Dec 7. doi: 10.1111/jep.12486. [Epub ahead of print]
- 58) Djulbegovic M, Mhaskar R, Reljic T, Ackerman RS, Miladinovic B, Lai A, **Hozo I**, Dahm P, Kumar A, “*Intravesical therapy for non-muscle invasive bladder cancer: a network meta-analysis (Protocol)*”, Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD012275. DOI: 10.1002/14651858.CD012275.
- 59) Benjamin Djulbegovic, Athanasios Tsalatsanis, Rahul Mhaskar, **Iztok Hozo**, Branko Miladinovic, Howard Tuch, “*Eliciting regret improves decision making at the end of life*”, European Journal of Cancer 68 (2016) 27e37; <http://dx.doi.org/10.1016/j.ejca.2016.08.027>
- 60) **Iztok Hozo**, Athanasios Tsalatsanis, Benjamin Djulbegovic, “*Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account*”, J Eval Clin Pract (2016); 1–7, DOI 10.1111/jep.12676
- 61) **Iztok Hozo**, Benjamin Djulbegovic, Shenghua Luan, Athanasios Tsalatsanis and Gerd Gigerenzer “*Towards theory integration: Threshold model as a link between signal detection theory, fast-and-frugal trees and evidence accumulation theory*” Journal of Evaluation in Clinical Practice ISSN 1365-2753 (2017)


- 62) **Iztok Hozo**, Athanasios Tsalatsanis, Benjamin Djulbegovic, “*Monte Carlo Decision Curve Analysis Using Aggregate Data*”, European journal of clinical investigation 47 (2), (2017) 176-183
- 63) A Tsalatsanis, **I Hozo**, B Djulbegovic, “*Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations.*” European Journal of Cancer 75, (2017) 159-166
- 64) B Djulbegovic, A Tsalatsanis, **I Hozo**, “*Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease*”, Journal of evaluation in clinical practice 23 (2), (2017) 241-250
- 65) T Mayrhofer, RM Hamm, J Van den Ende, **I Hozo**, B Djulbegovic, “*The predicament of patients with suspected Ebola*”, The Lancet Global Health 5 (7), e657 (2017).
- 66) Djulbegovic B, **Hozo I**, Dle B “*Transforming Clinical Practice Guidelines and Clinical Pathways into Fast-and-Frugal Decision Trees to Improve Clinical Care Strategies*”, Journal of Evaluation in Clinical Practice Volume: 24 Issue: 5 Special Issue: SI Pages: 1247-1254 Published: OCT 2018
- 67) RG Sinkey , J Lacevic, T Reljic, **I Hozo**, KS Gibson, AO Odibo, B Djulbegovic, CJ Lockwood “*Elective induction of labor at 39 weeks among nulliparous women: The impact on maternal and neonatal risk*”, PLoS ONE 13(4) (2018): e0193169. <https://doi.org/10.1371/journal.pone.0193169>
- 68) B Djulbegovic, T Reljic, Selqayam, A Cuker, **I Hozo**, Q Zhou, S Li, P Alexander, N Robby, W Wiercioch, H Schünemann and G Guyatt “*How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations*”, Blood 2018 132:4707; doi: <https://doi.org/10.1182/blood-2018-99-110132>
- 69) B Djulbegovic, **I Hozo**, T Mayrhofer, J Van den Ende, G Guyatt, “*The Threshold Model Revisited*” (2019) J Eval Clin Pract.; Published: 2019-May-07 (Epub 2019 May 07)
- 70) B Djulbegovic, **I Hozo**, “*A forgotten gamma error*” (2019) J Eval Clin Pract.;1–10. DOI: 10.1111/jep.13091
- 71) Djulbegovic B, **Hozo I**, “*Statins for Primary Prevention of Cardiovascular Disease*”. Annals of Internal Medicine Vol. 171 No. 1 pp 73-74.(2019)
- 72) Dziarski R, Banskar S, Detzner AA, Juarez-Rodriguez MD, **Hozo I**, Gupta D, “*Pglyrp1-Regulated Microbiome Enhances Experimental Allergic Asthma*”, The Journal of Immunology, J Immunol December 15, 2019, 203 (12) 3113-3125; DOI: <https://doi.org/10.4049/jimmunol.1900711>
- 73) B Djulbegovic, T Reljic, S Elqayam, A Cuker, **I Hozo**, Qi Zhou, SA Li, P Alexander, R Nieuwlaat, W Wiercioch, H Schünemann, G Guyatt, “*Structured decision-making drives guidelines panels' recommendations “for” but not “against” health interventions*”. Journal of Clinical Epidemiology (June 2019) Volume 110, Pages 23–33 DOI: <https://doi.org/10.1016/j.jclinepi.2019.02.009>
- 74) Salgia R, Mambetsariev I, Pharaon R, Fricke J, Baroz A, **Hozo I**, Chen C, Koczywas M, Massarelli E, Reckamp K, Djulbegovic B, “*Evaluation of omics-based strategies for the management of advanced lung cancer*” JCO Oncology Practice (July 2020)
- 75) Djulbegovic B, **Hozo I**, Weiss DJ, “*Evaluation of the US governors' decision when to issue stay-at-home orders*” Journal of Evaluation in Clinical Practice (published: August 2020)
- 76) Tsalatsanis A, **Hozo I**, Djulbegovic B. “*Meta-Analysis of mutual information applied in EBM diagnostics*”. Journal of Evaluation in Clinical Practice (published: September 2020). <https://doi.org/10.1111/jep.13475>
- 77) Djulbegovic B, Razavi M, **Hozo I**. “*When are randomized trials unnecessary? A signal detection theory approach to approving new treatments based on non-randomized studies.*”, Journal of Clinical

- 78) Djulbegovic B, **Hozo I**, Li Shelly-Anne, Razavi M, Cuker A, Guyatt G. “*Certainty of evidence and intervention's benefits & harms are key determinants of guidelines' recommendations.*”, J Eval Clin Pract. (published: March 2021); <https://doi.org/10.1016/j.jclinepi.2021.02.025>
- 79) Li SA , Yousefi-Nooraie R, Guyatt G , Talwar G, Wang Q , Zhu Y, **Hozo I** , Djulbegovic B. “*A few panel members dominated guideline development meeting discussions: Social network analysis*” Journal of Clinical Epidemiology 141 (2022) 1–10
- 80) Djulbegovic B, **Hozo I** , Guyatt G. “*Evidence, values, and masks for control of COVID-19*”, Journal of Clinical Epidemiology 131 (2022) 152e157
- 81) Djulbegovic B, **Hozo I** , at al.. “*High quality (certainty) evidence changes less often than low-quality evidence, but the magnitude of effect size does not systematically differ between studies with low versus high-quality evidence*” DOI: 10.1111/jep.13657 J Eval Clin Pract. (2022);1–10.
- 82) Tatiane Bomfim Ribeiro , Luis Enrique Colunga-Lozano , Ana Paula Vieira Araujo , Charles Lee Bennett , **Iztok Hozo** , Benjamin Djulbegovic , “*Single-arm clinical trials that supported FDA Accelerated Approvals have modest effect sizes and at high risk of bias*”, Journal of Clinical Epidemiology (2022), doi: <https://doi.org/10.1016/j.jclinepi.2022.01.018>
- 83) I. Hozo, B Djulbegovic, A Parish, J Ioannidis, “*Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible*”, Journal of Clinical Epidemiology 145 (2022) 101-111. <https://doi.org/10.1016/j.jclinepi.2022.01.016>
- 84) Djulbegovic B, **Hozo I**, Lizarraga D, Thomas J, Barbee M, Shah N, Reiser J, Guyatt G, “*Evaluation of a fast-and-frugal clinical decision algorithm (“pathways”) on clinical outcomes in hospitalized patients with COVID19 treated with anticoagulants*”, Journal of Evaluation in Clinical Practice (2022) <https://doi.org/10.1111/jep.13780> ” J Eval Clin Pract. 2022;1–1
- 85) Djulbegovic B, **Hozo I** , Guyatt G. “*Evidence, values, and masks for control of COVID-19: 2 years later*”, Journal of Clinical Epidemiology (2022) <https://doi.org/10.1016/j.jclinepi.2022.10.008>
- 86) John P.A. Ioannidis, **Iztok Hozo**, Benjamin Djulbegovic. “*Federal Funding and Citation Metrics of US Biomedical Researchers, 1996-2022*”, JAMA Network Open (2022): e2245590.doi: 10.1001/jamanetworkopen.2022.45590
- 87) Djulbegovic B, **Hozo I** , Lizarraga D, Guyatt G. “*Decomposing clinical practice guidelines panels' deliberation into decision theoretical constructs*” J Eval Clin Pract. 2023;1-13. doi:10.1111/jep.13809
- 88) Alessandro Cucchetti, Benjamin Djulbegovic, Stefano Crippa, **Iztok Hozo**, Monica Sbrancia, Athanasios Tsalatsanis, at al., “*Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer*”, Surgery, 2023, ISSN 0039-6060, <https://doi.org/10.1016/j.surg.2023.01.016>.
- 89) Djulbegovic B, **Hozo I** , Mandrolia J. “*Sorites paradox and persistence in overuse and underuse in healthcare delivery services*”. Journal of Evaluation in Clinical Practice. 2023; doi: 10.1111/jep.13851
- 90) Tatiane Bomfim Ribeiro, Charles L. Bennett, Luis Enrique Colunga-Lozano, Ana Paula Vieira Araujo, **Iztok Hozo**, Benjamin Djulbegovic, “*Increasing FDA Accelerated approval of Single-Arm Trials in Oncology (1992 to 2020)*”, Journal of Clinical Epidemiology, 2023, ISSN 0895-4356, <https://doi.org/10.1016/j.jclinepi.2023.04.001>.
- 91) **Hozo I**, Djulbegovic B. “*Generalized decision curve analysis for explicit comparison of treatment effects*”. J Eval Clin Pract. 2023;1-8. doi:10.1111/jep.13915
- 92) **Hozo I**, Guyatt G, Djulbegovic B, “*Decision curve analysis based on summary data*”, J Eval Clin Pract. 2023;1-9. doi:10.1111/jep.13945

- 93) Djulbegovic B, **Hozo I**, “*Threshold Decision-making in Clinical Medicine With Practical Application to Hematology and Oncology*”, **BOOK** publisher: SPRINGER, Part of the book series: Cancer Treatment and Research (CTAR, volume 189), ISBN 978-3-031-37992-5, <https://doi.org/10.1007/978-3-031-37993-2>
- 94) Djulbegovic B, **Hozo I**, Cuker A, Guyatt G. “*Improving methods of clinical practice guidelines: from guidelines to pathways to fast-and-frugal trees and decision analysis to develop individualised patient care.*” J Eval Clin Pract. 2024;30:393-402. doi:10.1111/jep.13953
- 95) Djulbegovic B; Boylan A; Kolo SJ; Bowen Scheurer D; Anuskiewicz S; Khaledi F; Youkhana K; Madgwick S; Maharjan N; **Hozo I** “*Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for VTE prophylaxis.*” Blood Adv First Edition April 2024. doi: 10.1182/bloodadvances.2024013166
- 96) Djulbegovic B, **Hozo I** and Guyatt G. “*Decision theoretical foundation of clinical practice guidelines: an extension of the ASH thrombophilia guidelines*”. Blood Adv bloodadvances.2024012931. <https://doi.org/10.1182/bloodadvances.2024012931>
- 97) Djulbegovic B, Koletsis D, **Hozo I**, Price A, Martimbianco ALC, Riera R, Nadanovsky P, dos Santos APP, Pandis N, Pacheco RL, Fontes LE, Seehra J, Ahmed M, Yao L, Nunan D, Hemkens LG, “*High certainty evidence is stable and trustworthy, whereas evidence of moderate or lower certainty may be equally prone to being unstable*”, Journal of Clinical Epidemiology (2024), doi: <https://doi.org/10.1016/j.jclinepi.2024.111392>.
- 98) **Hozo I**, Djulbegovic B. “*Thrombophilia Management Calculator*”, Blood Adv bloodadvances.2024013463. <https://doi.org/10.1182/bloodadvances.2024013463>
- 99) Chiara Alessandra Cella, Benjamin Djulbegovic, **Iztok Hozo**, Florian Lordick, Vincenzo Bagnardi, Samuele Frassoni, Lorenzo Gervaso ,Nicola Fazio. “*Comparison of Khorana vs. ONKOTEV Predictive Score to Individualize Anticoagulant Prophylaxis in Outpatients with Cancer*”, Published July 25 2024. DOI: <https://doi.org/10.1016/j.ejca.2024.114234>
- 100) Paczesny S, **Hozo I**, Djulbegovic B., “*Biomarker-derived Fast-and-frugal decision tree for preemption of Venous-occlusive Disease/Sinusoidal obstructive syndrome*”, Blood Advances (in print)

Citation Analysis:

	All	Since 2019
Citations	12065	7463
h-index	33	21
i10-index	62	48



According to the least exclusive (most generous) research search engine, [Google Scholar](https://scholar.google.com), as of September 5,

2024, there are **12065** citations of my papers – as shown in the table above. The number of annual citations seems to have reached about 1000 per year as seen on the graph, produced by Google Scholar:

(Definitions: **h-index** is the maximum number for which we can state that there are h research articles with at least h citations. **i10-index** is simply the number of articles with 10 or more citations.) Therefore, according to Google Scholar, 33 of my articles have 33 or more citations, and 62 of my articles have at least 10 citations.